A detailed history of Pale Fire Capital Se transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Pale Fire Capital Se holds 43,723 shares of TCRX stock, worth $180,138. This represents 0.03% of its overall portfolio holdings.

Number of Shares
43,723
Previous 21,573 102.67%
Holding current value
$180,138
Previous $126 Million 72.53%
% of portfolio
0.03%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.97 - $7.49 $110,085 - $165,903
22,150 Added 102.67%
43,723 $218 Million
Q4 2023

Feb 13, 2024

BUY
$2.66 - $6.76 $13,294 - $33,786
4,998 Added 30.15%
21,573 $126 Million
Q3 2023

Nov 13, 2023

BUY
$2.04 - $2.94 $33,813 - $48,730
16,575 New
16,575 $42.4 Million

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $78M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Pale Fire Capital Se Portfolio

Follow Pale Fire Capital Se and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pale Fire Capital Se, based on Form 13F filings with the SEC.

News

Stay updated on Pale Fire Capital Se with notifications on news.